FDA Awaits More Effexor Data Following U.K. Regulatory Changes
Executive Summary
FDA is awaiting further data on Wyeth's Effexor following U.K. regulatory changes for the antidepressant
You may also be interested in...
U.K. eases up on Effexor
The U.K. Medicines & Healthcare products Regulatory Agency lessens restrictions for Wyeth's serotonin and norepinephrine reuptake inhibitor Effexor. New guidance narrows limitations for patients with heart problems to high-risk groups and advises specialist supervision only for doses of 300 mg or more. Previous guidance was based on evidence of increased risk of overdose-related deaths and other risks (1"The Pink Sheet" Dec. 13, 2004, p. 7)...
U.K. eases up on Effexor
The U.K. Medicines & Healthcare products Regulatory Agency lessens restrictions for Wyeth's serotonin and norepinephrine reuptake inhibitor Effexor. New guidance narrows limitations for patients with heart problems to high-risk groups and advises specialist supervision only for doses of 300 mg or more. Previous guidance was based on evidence of increased risk of overdose-related deaths and other risks (1"The Pink Sheet" Dec. 13, 2004, p. 7)...
GSK Wellbutrin XL Ad Notes Suicidality Risk, Does Not Reflect “Black Box”
A new GlaxoSmithKline television ad for the antidepressant Wellbutrin XL includes information about suicidality and mood changes